CRDL News and Press, Cardiol Therapeutics Inc. From 04/20/25

2025-04-20 18:48:53 ET Cardiol Therapeutics Inc. (CRDL) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.99%. The average open to low on the day of earnings was -4.35%. The average open...

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes th...

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial Completed patient enrollment in the Phase II ARCHER trial evaluati...

2025-03-27 09:05:00 ET Quantum BioPharma (NASDAQ: QNTM) has appointed Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will remain as an advisor. Lynch, a prominent advocate against micro-cap stock manipulation and CEO of Power Nickel (TSXV: PNPN), brings deep exp...

Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased t...

Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardio...

2025-02-19 00:13:10 ET Summary Cardiol Therapeutics' CardiolRx™ shows promise in treating heart conditions, with ongoing clinical trials for pericarditis, myocarditis, and heart failure, and orphan drug status boosting its potential. Despite a 40% stock price decline, the m...

Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatme...